August 20, 2020: Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical trials to get us across that finish line.
CAR-T therapy should and will be a significant part of CLL treatment, hopefully in the not too distant future
For now, our friends with a sister B cell lymphoma, Mantle Cell Lymphoma, have reason to celebrate.
Here is the link to FDA’ s official Press Release.
Related posts